公开(公告)号：EP0843671A1

公开(公告)日：1998-05-27

申请号：EP96925710.0

申请日：1996-07-11

申请人： GLAXO GROUP LIMITED

发明人： COCKERILL, George Stuart, Glaxo Wellcome plc ,  CARTER, Malcolm Clive, Glaxo Wellcome plc ,  McKEOWN, Stephen Karl, Glaxo Wellcome plc ,  VILE, Sadie ,  PAGE, Martin John, Glaxo Wellcome plc ,  HUDSON, Alan Thomas, Long Lodge Cottage ,  BARRACLOUGH, Paul ,  FRANZMANN, Karl Witold, 6 Northstead Road

IPC分类号： A61K31 ,  A61P7 ,  A61P9 ,  A61P35 ,  A61P43 ,  C07D401 ,  C07D403 ,  C07D405 ,  C07D491

CPC分类号： C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D491/04

摘要： The invention is directed toward substituted heteroaromatic compounds which are protein tyrosine kinase inhibitors, in particular to substituted quinolines and quinazolines. Methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and cancer.

公开(公告)号：EP0912570A1

公开(公告)日：1999-05-06

申请号：EP97930518.0

申请日：1997-07-11

申请人： GLAXO GROUP LIMITED

发明人： COCKERILL, George Stuart, Glaxo Wellcome plc ,  CARTER, Malcolm Clive, Glaxo Wellcome plc ,  GUNTRIP, Stephen Barry, Glaxo Wellcome plc ,  SMITH, Kathryn Jane, Glaxo Wellcome plc

IPC分类号： A61K ,  C07D ,  C07D215 ,  A61K31 ,  A61P17 ,  A61P35 ,  A61P43 ,  C07D209 ,  C07D231 ,  C07D235 ,  C07D401 ,  C07D407 ,  C07D471 ,  C07D493 ,  C07D519

CPC分类号： C07D493/08 ,  C07D209/08 ,  C07D231/56 ,  C07D235/08 ,  C07D401/06 ,  C07D407/12 ,  C07D471/04

摘要： Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S(O)m, wherein m is as defined above, the heterocyclic ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused, with the provisos that the heterocyclic ring does not form part of a purine and that the fused heterocyclic ring does not contain two adjacent O or S(O)m atoms. U represents a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S(O)m, wherein m is 0,1 or 2 and wherein the ring system is substituted by at least one independently selected R6 group and is optionally substituted by at least one indepenently selected R4 group, with the proviso that U does not represent phenyl; are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.

公开(公告)号：EP0912572A1

公开(公告)日：1999-05-06

申请号：EP97933661.0

申请日：1997-07-11

申请人： GLAXO GROUP LIMITED

发明人： COCKERILL, George Stuart, Glaxo Wellcome plc ,  CARTER, Malcolm Clive, Glaxo Wellcome plc ,  GUNTRIP, Stephen Barry, Glaxo Wellcome plc ,  SMITH, Kathryn Jane, Glaxo Wellcome plc

IPC分类号： A61K ,  C07D ,  A61K31 ,  A61P17 ,  A61P35 ,  A61P43 ,  C07C211 ,  C07C217 ,  C07C317 ,  C07D471

CPC分类号： C07D471/04 ,  C07C217/86 ,  C07C317/36

摘要： Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds in which one ring is a pyridine or pyrimidine of formula (I) are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.